BIOTECH: AZIONI VOLANO DOPO PUBBLICAZIONE STUDIO MEDICO
U.S.-traded shares of Novogen jumped 44 percent after the Australian drug company said studies confirmed a potential drug to treat melanoma, a type of skin cancer.
The company said: “No targeted therapy exists for the 50% of melanoma patients whose tumors do not have the BRAF mutation. But even where a response is obtained with a BRAF-inhibitor, resistance typically develops within a year of treatment. Therefore the development of a drug that kills melanoma cells irrespective of their BRAF or any other mutational status has become an urgent clinical imperative.”
At the moment shares of small-cap Novogen are up 42% to $6.42 in pre-market trading following the company’s report on the studies.
Breaking news
Finale poco mosso a Piazza Affari, in rimonta rispetto all’apertura. Termina una settimana volatile, con focus su tensioni geopolitiche
Via libera dei soci Bper al nuovo cda e al dividendo
American Express ha chiuso il primo trimestre con ricavi sostanzialmente in linea con le attese e utili per azione sopra le aspettative
Borgosesia ha avviato negoziazione esclusiva per acquisire OneOSix, società specializzata nell’acquisto e gestione di crediti deteriorati
